| PRTC Stock | | | 169.40 3.80 2.29% |
Founder
David Elmaleh is CoFounder Advisor of PureTech Health plc
| Age | 76 |
| Address | 6 Tide Street, Boston, MA, United States, 02210 |
| Phone | 617 482 2333 |
| Web | https://www.puretechhealth.com |
PureTech Health Management Efficiency
The company has return on total asset
(ROA) of
(0.1339) % which means that it has lost $0.1339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.2207) %, meaning that it generated substantial loss on money invested by shareholders. PureTech Health's management efficiency ratios could be used to measure how well PureTech Health manages its routine affairs as well as how well it operates its assets and liabilities.
Non Currrent Assets Other is likely to gain to about 149.9
M in 2024, whereas
Total Assets are likely to drop slightly above 544.9
M in 2024.
PureTech Health plc (PRTC) is traded on London Exchange in UK and employs 90 people. PureTech Health is listed under Life Sciences Tools & Services category by Fama And French industry classification.
Management Performance
PureTech Health plc Leadership Team
Elected by the shareholders, the PureTech Health's board of directors comprises two types of representatives: PureTech Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PureTech. The board's role is to monitor PureTech Health's management team and ensure that shareholders' interests are well served. PureTech Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PureTech Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anita JD, Senior Property | |
| Lauren MBA, Chief Officer | |
| David Elmaleh, CoFounder Advisor | |
| Eric Elenko, CoFounder President | |
| Spencer Ball, Senior Resources | |
| III JD, General Secretary | |
| Joseph Bolen, Chief Officer | |
| Aleksandra MD, Head Oncology | |
| Daphne Zohar, Senior Founder | |
| Eric MBA, Chief Officer | |
| Dilip Kodira, Head Science | |
| Allison Talbot, Head Relations | |
| Dr Langer, CoFounder Director | |
| Bennett MD, CoFounder Advisor | |
| Cheryl Murphy, Head Strategy | |
| Dr JD, Secretary, President | |
PureTech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PureTech Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for PureTech Stock Analysis
When running PureTech Health's price analysis, check to
measure PureTech Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PureTech Health is operating at the current time. Most of PureTech Health's value examination focuses on studying past and present price action to
predict the probability of PureTech Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PureTech Health's price. Additionally, you may evaluate how the addition of PureTech Health to your portfolios can decrease your overall portfolio volatility.